Pfizer Stock Price, News & Analysis (NYSE:PFE)

$36.58 0.37 (1.02 %)
(As of 12/13/2017 01:57 AM ET)
Previous Close$36.21
Today's Range$36.25 - $36.82
52-Week Range$30.90 - $36.82
Volume22.49 million shs
Average Volume19.93 million shs
Market Capitalization$218.37 billion
P/E Ratio14.3
Dividend Yield3.58%
Beta1.01

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:PFE
CUSIP71708110
Phone+1-212-5732323

Debt

Debt-to-Equity Ratio0.56%
Current Ratio1.43%
Quick Ratio1.15%

Price-To-Earnings

Trailing P/E Ratio14.3
Forward P/E Ratio14.12
P/E Growth2.52

Sales & Book Value

Annual Sales$52.82 billion
Price / Sales4.13
Cash Flow$3.46 per share
Price / Cash10.57
Book Value$9.86 per share
Price / Book3.71

Profitability

Trailing EPS$1.63
Net Income$7.22 billion
Net Margins18.69%
Return on Equity25.41%
Return on Assets8.90%

Miscellaneous

Employees96,500
Outstanding Shares5,960,710,000

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Wednesday, September 27th. Stockholders of record on Friday, November 10th will be paid a dividend of $0.32 per share on Friday, December 1st. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date of this dividend is Thursday, November 9th. View Pfizer's Dividend History.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.65 by $0.02. The biopharmaceutical company earned $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm's quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.61 earnings per share. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Monday, January, 29th 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY17 earnings guidance on Tuesday, October, 31st. The company provided earnings per share guidance of $2.58-2.62 for the period, compared to the Thomson Reuters consensus estimate of $2.56. The company issued revenue guidance of $52.4-53.1 billion, compared to the consensus revenue estimate of $52.76 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?

16 Wall Street analysts have issued 12-month target prices for Pfizer's stock. Their predictions range from $31.00 to $53.00. On average, they expect Pfizer's stock price to reach $38.60 in the next twelve months. View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. According to Zacks Investment Research, "Pfizer is facing headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Additionally, Pfizer’s shares have underperformed the industry this year so far. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. The company has a mixed record of earnings surprises in recent quarters. Estimates have remained stable ahead of its Q3 earnings results." (10/11/2017)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 3. UBS AG analysts commented, " The FDA approved Novartis' CDK4/6 agent, Kisqali (ribociclib), in first-line treatment for HR+/HER2- metastatic breast cancer in combo with any aromatase inhibitor. Recall that MONALEESA-2 was stopped early, and while interim data demonstrated a reduction in risk of disease progression or death by 44% over letrozole alone, the mPFS had not been reached at the time. For the first time, the label presented a mPFS of 25.3 mos for Kisqali + letrozole vs 16 mos for letrozole alone. The 9.3 mos improvement over letrozole is essentially comparable to 10.3 mos improvement (24.8 mos for Ibrance vs 14.5 mos for letrozole) for Pfizer's Ibrance. Given the strong interim data that were comparable to Ibrance, we believe the approval of Kisqali was largely expected. Our takeaway: Label looks a little worse than Ibrance. Overall, we think the label looks slightly worse, particularly on safety. On the positive, the label is broader, as the indication is for use of Kisqali in combo with anyaromatase inhibitors (vs Ibrance in combo with letrozole). However, as the vast majority of first-line use letrozole, the broader label shouldn't meaningfully impact Ibrance, in our view. We're not clear on how Kisqali got the broader label, but we think this could be encouraging for Ibrance, as the Ibrance label could also become as broad with the potential April approval of the confirmatory Phase 3 PALOMA-2 (Ibrance was approved under an accelerated pathway with Phase 2 PALOMA-1 data). On safety, the Kisqali label warns of QT prolongation and liver tox, which are not in the Ibrance label. We think the QT issue could put Kisqali at a disadvantage. Thoughts on the stock: Shouldn't impact the stock much, if anyIbrance has been on the market for ~2 years and has made significant headway to becoming a standard of therapy, and we do not believe there was anything in the Kisqali label that would meaningfully impact the significant lead that Pfizer has. In our CDK4/6 model, we assign a 5% share for Kisqali in 2017 that goes to 15%, 18%, and 20% in 2018-2020E." (3/14/2017)
  • 4. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Are investors shorting Pfizer?

Pfizer saw a drop in short interest in the month of November. As of November 30th, there was short interest totalling 50,038,556 shares, a drop of 8.7% from the November 15th total of 54,814,537 shares. Based on an average daily trading volume, of 13,059,924 shares, the days-to-cover ratio is presently 3.8 days. Currently, 0.8% of the shares of the stock are short sold.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer (Age 63)
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations (Age 59)
  • Albert Bourla, Chief Operating Officer (Age 56)
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development (Age 58)
  • John D. Young, Group President - Pfizer Innovative Health and Angela Hwang (Age 53)
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer (Age 55)
  • Douglas M. Lankler, Executive Vice President, General Counsel (Age 51)
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources (Age 61)
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer (Age 62)
  • Kirsten Lund-Jurgensen, Executive Vice President, President - Pfizer Global Supply (Age 57)

Who owns Pfizer stock?

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.06%), Ameriprise Financial Inc. (1.01%), Barrow Hanley Mewhinney & Strauss LLC (0.75%), Dimensional Fund Advisors LP (0.72%), Fisher Asset Management LLC (0.59%) and Schwab Charles Investment Management Inc. (0.57%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Macquarie Group Ltd., APG Asset Management N.V., Janus Henderson Group PLC, Barrow Hanley Mewhinney & Strauss LLC, Schroder Investment Management Group, Brandes Investment Partners LP and Dimensional Fund Advisors LP. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Frank A Damelio, Ian C Read, Laurie J Olson, Mikael Dolsten, Rady A Johnson and Sally Susman. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was acquired by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Longview Partners Guernsey LTD, Boston Partners, Epoch Investment Partners Inc., Prudential Financial Inc., TD Asset Management Inc., Ameriprise Financial Inc. and Assenagon Asset Management S.A.. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $36.58.

How big of a company is Pfizer?

Pfizer has a market capitalization of $218.37 billion and generates $52.82 billion in revenue each year. The biopharmaceutical company earns $7.22 billion in net income (profit) each year or $1.63 on an earnings per share basis. Pfizer employs 96,500 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 E 42ND ST, NEW YORK, NY 10017-5703, United States. The biopharmaceutical company can be reached via phone at +1-212-5732323.


MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  885 (Vote Outperform)
Underperform Votes:  456 (Vote Underperform)
Total Votes:  1,341
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfizer (NYSE:PFE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.532.532.452.43
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.47$38.47$37.83$37.19
Price Target Upside: 8.37% upside10.09% upside7.89% upside13.36% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017BMO Capital MarketsSet Price TargetBuy$39.00LowView Rating Details
12/6/2017Deutsche BankSet Price TargetBuy$38.00LowView Rating Details
11/16/2017Jefferies GroupSet Price TargetNeutral$39.00N/AView Rating Details
11/1/2017J P Morgan Chase & CoSet Price TargetBuy$39.00N/AView Rating Details
11/1/2017Goldman Sachs GroupSet Price TargetNeutral$36.00N/AView Rating Details
10/31/2017Berenberg BankSet Price TargetNeutral$36.00N/AView Rating Details
10/11/2017BarclaysSet Price TargetBuy$38.00N/AView Rating Details
9/20/2017Morgan StanleyUpgradeEqual Weight -> Overweight$35.00 -> $39.00LowView Rating Details
9/19/2017Sanford C. BernsteinSet Price TargetBuy$39.00LowView Rating Details
8/14/2017CowenSet Price TargetBuy$43.00LowView Rating Details
7/20/2017Credit Suisse GroupDowngradeOutperform -> Neutral$38.00 -> $36.00LowView Rating Details
5/16/2017CitigroupDowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00LowView Rating Details
2/2/2017MorningstarReiterated RatingBuyN/AView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/7/2016Bank of AmericaReiterated RatingBuy$40.00 -> $36.00N/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
5/4/2016Independent ResearchSet Price TargetNeutral$37.00N/AView Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
2/16/2016SunTrust BanksLower Price TargetNeutral$37.00 -> $33.00N/AView Rating Details
1/26/2016Nord/LBReiterated RatingBuyN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/29/2018N/AView Earnings Details
10/31/2017Q3 2017$0.65$0.67$13.17 billion$13.17 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.08 billion$12.90 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Pfizer (NYSE:PFE) Earnings Estimates

2017 EPS Consensus Estimate: $2.51
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.67$0.67$0.67
Q2 20173$0.62$0.65$0.64
Q3 20173$0.64$0.65$0.64
Q4 20172$0.55$0.56$0.56
(Data provided by Zacks Investment Research)

Dividends

Pfizer (NYSE:PFE) Dividend Information

Most Recent Dividend:12/1/2017
Annual Dividend:$1.28
Dividend Yield:3.50%
Dividend Growth:7.70% (3 Year Average)
Payout Ratio:78.53% (Trailing 12 Months of Earnings)
49.42% (Based on This Year's Estimates)
46.72% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/27/2017quarterly$0.323.6%11/9/201711/10/201712/1/2017
6/22/2017quarterly$0.323.75%8/2/20178/4/20179/1/2017
4/28/2017quarterly$0.323.77%5/10/20175/12/20176/1/2017
12/12/2016quarterly$0.323.9%2/1/20172/3/20173/1/2017
9/23/2016quarterly$0.303.5%11/8/201611/11/201612/1/2016
6/23/2016quarterly$0.303.53%8/3/20168/5/20169/1/2016
4/28/2016quarterly$0.303.67%5/11/20165/13/20166/1/2016
12/14/2015quarterly$0.303.72%2/3/20162/5/20163/2/2016
9/25/2015quarterly$0.283.63%11/4/201511/6/201512/1/2015
6/25/2015quarterly$0.283.3%8/5/20158/7/20159/2/2015
4/23/2015quarterly$0.283.18%5/6/20155/8/20156/2/2015
12/15/2014quarterly$0.283.65%2/4/20152/6/20153/3/2015
10/23/2014quarterly$0.263.57%11/5/201411/7/201412/2/2014
6/26/2014quarterly$0.263.51%7/30/20148/1/20149/3/2014
4/25/2014quarterly$0.263.38%5/7/20145/9/20146/3/2014
12/16/2013quarterly$0.263.45%2/5/20142/7/20143/4/2014
10/24/2013quarterly$0.243.14%11/6/201311/8/201312/3/2013
6/27/2013quarterly$0.243.43%7/31/20138/2/20139/4/2013
4/25/2013quarterly$0.243.19%5/8/20135/10/20136/4/2013
12/17/2012quarterly$0.243.74%1/30/20132/1/20133/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 69.89%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Alexander R MackenzieInsiderSell14,700$35.30$518,910.00View SEC Filing  
10/2/2017Alexander R MackenzieEVPSell7,350$35.65$262,027.50View SEC Filing  
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.80View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.00View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.00View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.70View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
Pfizers (PFE) Talazoparib Emerges Superior in EMBRACA StudyPfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
finance.yahoo.com - December 12 at 4:50 PM
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA StudyPfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
finance.yahoo.com - December 12 at 4:50 PM
What Analysts Recommend for Eli Lilly in December 2017What Analysts Recommend for Eli Lilly in December 2017
finance.yahoo.com - December 12 at 10:50 AM
Pfizers (PFE) Talazoparib Emerges Superior in EMBRACA Study - NasdaqPfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study - Nasdaq
www.nasdaq.com - December 11 at 4:43 PM
Heres Why Spark Therapeutics, Inc. Is Getting Hammered TodayHere's Why Spark Therapeutics, Inc. Is Getting Hammered Today
www.fool.com - December 11 at 2:31 PM
Spark, Pfizer Record Sustained Factor IX Activity Levels In SPK-9001 TrialSpark, Pfizer Record Sustained Factor IX Activity Levels In SPK-9001 Trial
www.nasdaq.com - December 11 at 11:06 AM
The Little Blue Pill: An Oral History of ViagraThe Little Blue Pill: An Oral History of Viagra
finance.yahoo.com - December 11 at 11:06 AM
Tevas stock gains after exclusive launch of generic ViagraTeva's stock gains after exclusive launch of generic Viagra
finance.yahoo.com - December 11 at 11:06 AM
Sex, Drugs, and Teva Pharmaceutical Industries (TEVA)Sex, Drugs, and Teva Pharmaceutical Industries (TEVA)
finance.yahoo.com - December 11 at 11:06 AM
Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)
www.fool.com - December 10 at 9:40 AM
A Cancer-Drug Pricing Experiment Just Got More InterestingA Cancer-Drug Pricing Experiment Just Got More Interesting
finance.yahoo.com - December 8 at 4:30 PM
An Irish Town That Manufactures Viagra Boasts of ‘Love Fumes’ in the AirAn Irish Town That Manufactures Viagra Boasts of ‘Love Fumes’ in the Air
finance.yahoo.com - December 8 at 4:30 PM
Pfizer (PFE) Given a $39.00 Price Target at BMO Capital MarketsPfizer (PFE) Given a $39.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - December 8 at 11:58 AM
Pfizer: Talazoparib Extends Progression-Free Survival In Phase 3 TrialPfizer: Talazoparib Extends Progression-Free Survival In Phase 3 Trial
www.nasdaq.com - December 8 at 10:21 AM
Pfizer breast cancer drug superior to chemotherapy in late stage studyPfizer breast cancer drug superior to chemotherapy in late stage study
www.reuters.com - December 8 at 10:21 AM
CWABS Asset-Backed Certificates Trust 2007-6 -- Moodys assigns A1 to Pfizers new sterling notes; stable outlookCWABS Asset-Backed Certificates Trust 2007-6 -- Moody's assigns A1 to Pfizer's new sterling notes; stable outlook
finance.yahoo.com - December 8 at 10:21 AM
Pfizer breast cancer drug superior to chemotherapy in Phase III studyPfizer breast cancer drug superior to chemotherapy in Phase III study
finance.yahoo.com - December 8 at 10:21 AM
Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast CancerTalazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
finance.yahoo.com - December 8 at 10:21 AM
Healthy Earnings Visibility Keep Pfizer (PFE) a BuyHealthy Earnings Visibility Keep Pfizer (PFE) a Buy
investorplace.com - December 8 at 8:23 AM
Pfizer is releasing its own generic Viagra to stay relevantPfizer is releasing its own generic Viagra to stay relevant
finance.yahoo.com - December 7 at 10:45 AM
Pfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors and (ii) Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of ConsentsPfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors and (ii) Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents
finance.yahoo.com - December 7 at 10:45 AM
Regulations And Politics Rain On Pharma M&A ParadeRegulations And Politics Rain On Pharma M&A Parade
finance.yahoo.com - December 7 at 10:45 AM
Gene therapy shows promise against blood-clotting diseaseGene therapy shows promise against blood-clotting disease
marketbeat.com - December 6 at 7:37 PM
Pfizer (PFE) Says Updated Data from Phase 3 Trial of IBRANCE Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in PFSPfizer (PFE) Says Updated Data from Phase 3 Trial of IBRANCE Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in PFS
www.streetinsider.com - December 6 at 10:40 AM
Frayed Gasket Delaying Astras ZS-9 Shows Pharma M&A PerilsFrayed Gasket Delaying Astra's ZS-9 Shows Pharma M&A Perils
finance.yahoo.com - December 6 at 10:40 AM
Pfizer Inc. breached its 50 day moving average in a Bearish Manner : PFE-US : December 6, 2017Pfizer Inc. breached its 50 day moving average in a Bearish Manner : PFE-US : December 6, 2017
finance.yahoo.com - December 6 at 10:40 AM
UBS Reiterates "$40.00" Price Target for Pfizer (PFE)UBS Reiterates "$40.00" Price Target for Pfizer (PFE)
www.americanbankingnews.com - December 6 at 10:28 AM
Pfizer (PFE) Given a $38.00 Price Target by Deutsche Bank AnalystsPfizer (PFE) Given a $38.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - December 6 at 9:38 AM
ETFs with exposure to Pfizer Inc. : December 5, 2017ETFs with exposure to Pfizer Inc. : December 5, 2017
finance.yahoo.com - December 5 at 4:30 PM
Dow Analyst Moves: PFEDow Analyst Moves: PFE
www.nasdaq.com - December 5 at 12:03 PM
Have you been 'pwned' in a data breach? Troy Hunt can tellHave you been 'pwned' in a data breach? Troy Hunt can tell
finance.yahoo.com - December 5 at 12:03 PM
Zacks: Brokerages Expect Pfizer Inc. (PFE) to Post $0.56 EPSZacks: Brokerages Expect Pfizer Inc. (PFE) to Post $0.56 EPS
www.americanbankingnews.com - December 4 at 11:26 PM
A Look at How These Pfizer Drugs Have Performed in 2017A Look at How These Pfizer Drugs Have Performed in 2017
finance.yahoo.com - December 4 at 4:33 PM
How Is Pfizer’s Sterile Injection Pharmaceuticals Business Positioned?How Is Pfizer’s Sterile Injection Pharmaceuticals Business Positioned?
finance.yahoo.com - December 4 at 10:23 AM
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal DrugPfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug
finance.yahoo.com - December 4 at 10:23 AM
3 Reasons Pfizer Should Buy Celgene in 20183 Reasons Pfizer Should Buy Celgene in 2018
www.fool.com - December 4 at 8:37 AM
Pfizer (PFE) Ranking Raised to Buy on Improving Earnings ... - Investorplace.comPfizer (PFE) Ranking Raised to Buy on Improving Earnings ... - Investorplace.com
investorplace.com - December 2 at 4:28 PM
Pfizer to commercialize antifungal Cresemba in Asia - Seeking AlphaPfizer to commercialize antifungal Cresemba in Asia - Seeking Alpha
seekingalpha.com - December 2 at 4:28 PM
Is a Dividend Cut Coming From GlaxoSmithKline plc?Is a Dividend Cut Coming From GlaxoSmithKline plc?
finance.yahoo.com - December 2 at 4:28 PM
How Pfizer’s Established Products Have PerformedHow Pfizer’s Established Products Have Performed
finance.yahoo.com - December 1 at 5:38 PM
How Pfizer’s Premarin and Other Legacy Established Products PerformedHow Pfizer’s Premarin and Other Legacy Established Products Performed
finance.yahoo.com - December 1 at 5:38 PM
Pfizer (PFE) Ranking Raised to Buy on Improving Earnings MomentumPfizer (PFE) Ranking Raised to Buy on Improving Earnings Momentum
investorplace.com - December 1 at 10:08 AM
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia PacificBasilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
feeds.benzinga.com - December 1 at 1:54 AM
How Have Pfizer’s Ibrance and Sutent Performed in 2017?How Have Pfizer’s Ibrance and Sutent Performed in 2017?
finance.yahoo.com - November 30 at 11:00 AM
An Update on Pfizer’s Xalkori and InlytaAn Update on Pfizer’s Xalkori and Inlyta
finance.yahoo.com - November 30 at 11:00 AM
How Has Pfizer’s Internal Medicine Portfolio Performed in 2017?How Has Pfizer’s Internal Medicine Portfolio Performed in 2017?
finance.yahoo.com - November 30 at 11:00 AM
How Are Pfizer’s Vaccines and Biosimilars Positioned after 3Q17?How Are Pfizer’s Vaccines and Biosimilars Positioned after 3Q17?
finance.yahoo.com - November 29 at 4:46 PM
Bank of America Acts on Bristol-Myers Squibb and PfizerBank of America Acts on Bristol-Myers Squibb and Pfizer
finance.yahoo.com - November 29 at 4:46 PM
APNewsBreak: Doctor says drug scarcity drove execution planAPNewsBreak: Doctor says drug scarcity drove execution plan
marketbeat.com - November 29 at 3:03 PM
Pfizer/Merck KGaAs Bavencio Fails in Gastric Cancer StudyPfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study
www.zacks.com - November 29 at 10:27 AM

SEC Filings

Pfizer (NYSE:PFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pfizer (NYSE PFE) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.